Last reviewed · How we verify
FULVICIN P/G 330 (GRISEOFULVIN, ULTRAMICROSIZE)
FULVICIN P/G 330 (generic name: GRISEOFULVIN, ULTRAMICROSIZE) is a drug developed by CHARTWELL RX. It is currently FDA-approved for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis.
FULVICIN P/G 330 is a small molecule inhibitor that targets tubulin. It is classified as a tubulin inhibitor, which is a type of drug that works by interfering with the function of tubulin, a protein involved in cell division.
At a glance
| Generic name | GRISEOFULVIN, ULTRAMICROSIZE |
|---|---|
| Sponsor | CHARTWELL RX |
| Target | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Onychomycosis due to dermatophyte
- Tinea barbae
- Tinea capitis
- Tinea corporis
- Tinea cruris
- Tinea pedis
Common side effects
- Skin rashes
- Urticaria
- Nausea
- Vomiting
- Epigastric distress
- Diarrhea
- Headache
- Fatigue
- Dizziness
- Insomnia
- Mental confusion
- Impairment of performance of routine activities
Serious adverse events
- Erythema multiforme-like drug reactions
- Angioneurotic edema
- Severe skin adverse events
- Severe hepatic adverse events
- Proteinuria
- Leukopenia
- Granulocytopenia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FULVICIN P/G 330 CI brief — competitive landscape report
- FULVICIN P/G 330 updates RSS · CI watch RSS
- CHARTWELL RX portfolio CI
Frequently asked questions about FULVICIN P/G 330
What is FULVICIN P/G 330?
FULVICIN P/G 330 (GRISEOFULVIN, ULTRAMICROSIZE) is a pharmaceutical drug developed by CHARTWELL RX, indicated for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis.
What is FULVICIN P/G 330 used for?
FULVICIN P/G 330 is indicated for Onychomycosis due to dermatophyte, Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruris.
Who makes FULVICIN P/G 330?
FULVICIN P/G 330 is developed and marketed by CHARTWELL RX (see full CHARTWELL RX pipeline at /company/chartwell-rx).
What is the generic name of FULVICIN P/G 330?
GRISEOFULVIN, ULTRAMICROSIZE is the generic (nonproprietary) name of FULVICIN P/G 330.
What development phase is FULVICIN P/G 330 in?
FULVICIN P/G 330 is FDA-approved (marketed).
What are the side effects of FULVICIN P/G 330?
Common side effects of FULVICIN P/G 330 include Skin rashes, Urticaria, Nausea, Vomiting, Epigastric distress, Diarrhea. Serious adverse events: Erythema multiforme-like drug reactions, Angioneurotic edema, Severe skin adverse events, Severe hepatic adverse events.
What does FULVICIN P/G 330 target?
FULVICIN P/G 330 targets Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin.
Related
- Target: All drugs targeting Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
- Manufacturer: CHARTWELL RX — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Onychomycosis due to dermatophyte
- Indication: Drugs for Tinea barbae
- Indication: Drugs for Tinea capitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing